| Case Study 5 : | ||||||
| Compound 4 is a large protein. The drug is administered today by subcutaneous or intramuscular injection. Physica is developing a formulation of Compound 4 with improved permeability properties with the aim to deliver the drug through the nasal mucosa. |
||||||
| Chart 1:
The following chart illustrates how Biodis improved the drug permeability across nasal cells (in vitro model). |
||||||
| Drug concentration in basal chamber of nasal epithelium cell system |
||||||
 |